Cargando…

A case of reactivation of varicella–zoster virus after BNT162b2 vaccine second dose?

We report a case of itchy papulovesicular rash consistent with varicella–zoster virus reactivation after Pfizer-BioNTech vaccine second dose administration. While there have been cases of varicella–zoster virus reactivation due to COVID-19 or COVID-19 vaccine inoculation in older individuals with pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santovito, Luca Spiro, Pinna, Graziano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364300/ https://www.ncbi.nlm.nih.gov/pubmed/34390376 http://dx.doi.org/10.1007/s00011-021-01491-w

Ejemplares similares

Varicella zoster virus reactivation during or immediately following treatment of tegumentary leishmaniasis with antimony compounds
por: Barros, Andrea Barbieri, et al.
Publicado: (2014)

Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection
por: Baos, Elvira, et al.
Publicado: (2022)

Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
por: Kontopoulou, Konstantina, et al.
Publicado: (2021)

Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases
por: Rodríguez-Jiménez, Pedro, et al.
Publicado: (2021)

Response to “Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases”
por: Lim, Ziying Vanessa, et al.
Publicado: (2022)

Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2022)

Acute reduction of visual acuity and visual field after Pfizer-BioNTech COVID-19 vaccine 2nd dose: a case report
por: Santovito, Luca Spiro, et al.
Publicado: (2021)

IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies
por: Malavige, G N, et al.
Publicado: (2010)

Association between quantitative varicella-zoster virus antibody levels and zoster reactivation in HIV-infected persons
por: Pomerantz, Heather S., et al.
Publicado: (2018)

Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine
por: Raw, Rachael K., et al.
Publicado: (2022)

The fraction of varicella zoster virus-specific antibodies among all intrathecally-produced antibodies discriminates between patients with varicella zoster virus reactivation and multiple sclerosis
por: Otto, Carolin, et al.
Publicado: (2014)

A case of varicella zoster virus meningitis following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient
por: Maruki, Taketomo, et al.
Publicado: (2021)

COVID-19 vaccination may reactivate varicella-zoster virus
Publicado: (2022)

Aseptic meningitis after BNT-162b2 COVID-19 vaccination
por: Chan, Amanda CY., et al.
Publicado: (2021)

Depressive symptoms predict antibody titers after a second dose of the SARS-CoV-2 BNT162b2 vaccine among hospital workers in Japan
por: Kaneko, Hiroshi, et al.
Publicado: (2023)

T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity
por: Casado, Jose L, et al.
Publicado: (2021)

Varicella zoster virus reactivation and mRNA vaccines as a trigger
por: Lladó, Iñigo, et al.
Publicado: (2021)

Varicella-Zoster Virus (VZV) Meningitis in an Immunocompetent Adult after BNT162b2 mRNA COVID-19 Vaccination: A Case Report
por: Medhat, R., et al.
Publicado: (2022)

Varicella zoster virus vaccines: an update
por: Gabutti, Giovanni, et al.
Publicado: (2019)

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon
por: Moghnieh, Rima, et al.
Publicado: (2021)

One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine
por: Wand, Ori, et al.
Publicado: (2023)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

Silent Reactivation of Varicella Zoster Virus in Pregnancy: Implications for Maintenance of Immunity to Varicella
por: Mourad, Mirella, et al.
Publicado: (2022)

Myelitis and Radiculitis Complicating Varicella-Zoster Virus Reactivation
por: Corrêa, Diogo Goulart, et al.
Publicado: (2020)

Tozinameran: Reactivation of varicella zoster virus: case report
Publicado: (2022)

Tozinameran: Varicella-zoster virus reactivation: case report
Publicado: (2022)

The Spectrum of Neurological Manifestations of Varicella–Zoster Virus Reactivation
por: Kennedy, Peter G. E.
Publicado: (2023)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2
por: Psichogiou, Mina, et al.
Publicado: (2021)

Identifying optimal vaccination scenarios to reduce varicella zoster virus transmission and reactivation
por: Bakker, Kevin M, et al.
Publicado: (2022)

BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity
por: Vizcarra, Pilar, et al.
Publicado: (2021)

Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis
por: Michos, Athanasios, et al.
Publicado: (2022)

Real‐world evidence from over one million COVID‐19 vaccinations is consistent with reactivation of the varicella‐zoster virus
por: Hertel, M., et al.
Publicado: (2022)

Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection
por: Bongiovanni, Marco, et al.
Publicado: (2021)

The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
por: Maldonado, M.D., et al.
Publicado: (2021)

2767. Variation in Incidence of Pediatric Herpes Zoster by First- and Second-Dose Varicella Vaccine Formulations
por: Weinmann, Sheila, et al.
Publicado: (2019)

Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea
por: Lee, Yun Woo, et al.
Publicado: (2021)

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
por: Robertson, John F R, et al.
Publicado: (2021)

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
por: Zaqout, Ahmed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qfgilrueank2v740pv3d916fc7